Hepatocarcinoma in cirrhosis - Is antithrombin III a neoplastic marker?

A. Grieco, V. De Stefano, A. Cassano, A. Ciabattoni, C. Garufi, A. Astone, G. Leone, C. Barone

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

It has been reported that hepatoma (HCC) cells produce abnormal proteins such as erytropietin, fibrinogen, prothrombin, and recently, antithrombin III (AT III). In a preliminary report, we reported increased AT III levels in patients bearing HCC independent of their clinical liver status. The present study was performed to assess antithrombin III levels and other serological data present in patients with cirrhosis and in patients with cirrhosis and clinical findings of neoplastic disease. In 70 well-matched patients (47 with cirrhosis and 23 with cirrhosis and proven HCC) serum total cholesterol, albumin, prothrombin, alkaline phosphatase, AFP, aminotransferases, and AT III were determined. Together with AFP and alkaline phosphatase, patients with HCC had higher values of AT III (88±7%) and total cholesterol (184±17 mg/100 ml), as compared with cirrhotic patients (AT III 56±3.6%; total cholesterol 113±5 mg/100 ml) (P2=0.317), whereas in the cirrhotic patients it correlated with the prothrombin level (R2=0.274). These data suggest that in HCC patients a greater rate of synthesis of AT III occurs, whereas in cirrhotic patients lower levels of AT III occur due to impaired synthesis or increased catabolism of the protein. The serial determination of AT III in cirrhotic patients as a means of detecting neoplastic transformation is suggested.

Original languageEnglish
Pages (from-to)990-992
Number of pages3
JournalDigestive Diseases and Sciences
Volume36
Issue number7
DOIs
Publication statusPublished - Jul 1991

Fingerprint

Antithrombin III
Fibrosis
Prothrombin
Cholesterol
Alkaline Phosphatase
Transaminases
Fibrinogen
Albumins
Hepatocellular Carcinoma
Proteins

Keywords

  • antithrombin III
  • cirrhosis
  • hepatocarcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Grieco, A., De Stefano, V., Cassano, A., Ciabattoni, A., Garufi, C., Astone, A., ... Barone, C. (1991). Hepatocarcinoma in cirrhosis - Is antithrombin III a neoplastic marker? Digestive Diseases and Sciences, 36(7), 990-992. https://doi.org/10.1007/BF01297153

Hepatocarcinoma in cirrhosis - Is antithrombin III a neoplastic marker? / Grieco, A.; De Stefano, V.; Cassano, A.; Ciabattoni, A.; Garufi, C.; Astone, A.; Leone, G.; Barone, C.

In: Digestive Diseases and Sciences, Vol. 36, No. 7, 07.1991, p. 990-992.

Research output: Contribution to journalArticle

Grieco, A, De Stefano, V, Cassano, A, Ciabattoni, A, Garufi, C, Astone, A, Leone, G & Barone, C 1991, 'Hepatocarcinoma in cirrhosis - Is antithrombin III a neoplastic marker?', Digestive Diseases and Sciences, vol. 36, no. 7, pp. 990-992. https://doi.org/10.1007/BF01297153
Grieco A, De Stefano V, Cassano A, Ciabattoni A, Garufi C, Astone A et al. Hepatocarcinoma in cirrhosis - Is antithrombin III a neoplastic marker? Digestive Diseases and Sciences. 1991 Jul;36(7):990-992. https://doi.org/10.1007/BF01297153
Grieco, A. ; De Stefano, V. ; Cassano, A. ; Ciabattoni, A. ; Garufi, C. ; Astone, A. ; Leone, G. ; Barone, C. / Hepatocarcinoma in cirrhosis - Is antithrombin III a neoplastic marker?. In: Digestive Diseases and Sciences. 1991 ; Vol. 36, No. 7. pp. 990-992.
@article{e0acd9b72d6b438eb48862eb6f9798ad,
title = "Hepatocarcinoma in cirrhosis - Is antithrombin III a neoplastic marker?",
abstract = "It has been reported that hepatoma (HCC) cells produce abnormal proteins such as erytropietin, fibrinogen, prothrombin, and recently, antithrombin III (AT III). In a preliminary report, we reported increased AT III levels in patients bearing HCC independent of their clinical liver status. The present study was performed to assess antithrombin III levels and other serological data present in patients with cirrhosis and in patients with cirrhosis and clinical findings of neoplastic disease. In 70 well-matched patients (47 with cirrhosis and 23 with cirrhosis and proven HCC) serum total cholesterol, albumin, prothrombin, alkaline phosphatase, AFP, aminotransferases, and AT III were determined. Together with AFP and alkaline phosphatase, patients with HCC had higher values of AT III (88±7{\%}) and total cholesterol (184±17 mg/100 ml), as compared with cirrhotic patients (AT III 56±3.6{\%}; total cholesterol 113±5 mg/100 ml) (P2=0.317), whereas in the cirrhotic patients it correlated with the prothrombin level (R2=0.274). These data suggest that in HCC patients a greater rate of synthesis of AT III occurs, whereas in cirrhotic patients lower levels of AT III occur due to impaired synthesis or increased catabolism of the protein. The serial determination of AT III in cirrhotic patients as a means of detecting neoplastic transformation is suggested.",
keywords = "antithrombin III, cirrhosis, hepatocarcinoma",
author = "A. Grieco and {De Stefano}, V. and A. Cassano and A. Ciabattoni and C. Garufi and A. Astone and G. Leone and C. Barone",
year = "1991",
month = "7",
doi = "10.1007/BF01297153",
language = "English",
volume = "36",
pages = "990--992",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Hepatocarcinoma in cirrhosis - Is antithrombin III a neoplastic marker?

AU - Grieco, A.

AU - De Stefano, V.

AU - Cassano, A.

AU - Ciabattoni, A.

AU - Garufi, C.

AU - Astone, A.

AU - Leone, G.

AU - Barone, C.

PY - 1991/7

Y1 - 1991/7

N2 - It has been reported that hepatoma (HCC) cells produce abnormal proteins such as erytropietin, fibrinogen, prothrombin, and recently, antithrombin III (AT III). In a preliminary report, we reported increased AT III levels in patients bearing HCC independent of their clinical liver status. The present study was performed to assess antithrombin III levels and other serological data present in patients with cirrhosis and in patients with cirrhosis and clinical findings of neoplastic disease. In 70 well-matched patients (47 with cirrhosis and 23 with cirrhosis and proven HCC) serum total cholesterol, albumin, prothrombin, alkaline phosphatase, AFP, aminotransferases, and AT III were determined. Together with AFP and alkaline phosphatase, patients with HCC had higher values of AT III (88±7%) and total cholesterol (184±17 mg/100 ml), as compared with cirrhotic patients (AT III 56±3.6%; total cholesterol 113±5 mg/100 ml) (P2=0.317), whereas in the cirrhotic patients it correlated with the prothrombin level (R2=0.274). These data suggest that in HCC patients a greater rate of synthesis of AT III occurs, whereas in cirrhotic patients lower levels of AT III occur due to impaired synthesis or increased catabolism of the protein. The serial determination of AT III in cirrhotic patients as a means of detecting neoplastic transformation is suggested.

AB - It has been reported that hepatoma (HCC) cells produce abnormal proteins such as erytropietin, fibrinogen, prothrombin, and recently, antithrombin III (AT III). In a preliminary report, we reported increased AT III levels in patients bearing HCC independent of their clinical liver status. The present study was performed to assess antithrombin III levels and other serological data present in patients with cirrhosis and in patients with cirrhosis and clinical findings of neoplastic disease. In 70 well-matched patients (47 with cirrhosis and 23 with cirrhosis and proven HCC) serum total cholesterol, albumin, prothrombin, alkaline phosphatase, AFP, aminotransferases, and AT III were determined. Together with AFP and alkaline phosphatase, patients with HCC had higher values of AT III (88±7%) and total cholesterol (184±17 mg/100 ml), as compared with cirrhotic patients (AT III 56±3.6%; total cholesterol 113±5 mg/100 ml) (P2=0.317), whereas in the cirrhotic patients it correlated with the prothrombin level (R2=0.274). These data suggest that in HCC patients a greater rate of synthesis of AT III occurs, whereas in cirrhotic patients lower levels of AT III occur due to impaired synthesis or increased catabolism of the protein. The serial determination of AT III in cirrhotic patients as a means of detecting neoplastic transformation is suggested.

KW - antithrombin III

KW - cirrhosis

KW - hepatocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=0025821273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025821273&partnerID=8YFLogxK

U2 - 10.1007/BF01297153

DO - 10.1007/BF01297153

M3 - Article

C2 - 1649042

AN - SCOPUS:0025821273

VL - 36

SP - 990

EP - 992

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 7

ER -